New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study.

J Med Genet · 2016 · PMC5099175 · PMID 27208206

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

However, a clear limitation of this analysis is the exclusion of the costs involved in the clinical management of these patients, which are likely to be significant when cascade testing is also included in the ‘patient’ pathway.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.